Oncosec is using a local injection–global effect model as their therapy, where electroporation of IL-12 is a nonviral therapy that has already shown interesting single-agent results when tested on its own, and is now studied in combination with anti PD-1. The trial is for patients that normally would not respond to anti PD-1 due to their low TIL s. It can be deduced from the patient’s complete response of the target lesion, shown in the PET imaging after only 2 cycles of IL-12 and a fourth cycle of pembrolizumab whith no other sites of disease by the fifth cycle of treatment, that the electroporation of the interleukin is helping to raise those TILs by stimulating the production of interferon gamma (IFN-y) resulting in the synergizing of anti PD-1.
PET imaging is a method of assessing the bio distribution of new biological compounds of therapeutic interest rapidly and is of great importance in the study. I mentioned previously the use of a tracer in the PET imaging for oncology and in this case, IL-12 acts as an immunoPET tracer to image PD-1 expressing TILs. One can conclude from those results that non-responders are responding.
Looking more into the subject, I found an interesting abstract that helped me understand the results and what Oncosec most likely accomplished.
News 
Market Data 
Discover 
